Cumberland Pharmaceuticals, Inc.

Vanderbilt University

Oncolytics Biotech Inc.

Biocon Limited

Cumberland Pharmaceuticls Inc.

Leo Pavliv

Amy Dix Rock

James West

Bryan Voss

Erica J Carrier

Andrew Vila

Matthew C Coffey

Sarah Serl

Mark A Miller

Nnochiri Ekwuribe

Balasingam Radhakrishnan

Navdeep Balkrishna Malkar

Kenneth D James

Karen Polowy

Monica Puskas

Michelle Ferro

Diti Aggarwal

Ines Macias-Perez

Zachary Cox

Nnochiri N Ekwuribe

Erica Carrier

Nnochiril N Ekwuribe

Karen Puskas

Nnochirii N Ekwuribe

The present invention is directed to methods of treating, preventing, and/or ameliorating fibrosis syndrome, and in particular cardiac fibrosis, by administration of a therapeutically effective amount of ifetroban, or a pharmaceutically acceptable salt thereof.

Compositions and methods of treating cardiac fibrosis with ifetroban

The present invention provides a pharmaceutical composition comprising an aqueous solution of an ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition. The invention further provides a method of treating a condition chosen from pain, inflammation, fever, and/or patent ductus arteriosis, comprising administering to a patient in need thereof an effective amount of an aqueous solution a ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition, as well as a method for manufacturing the composition.

Injectable ibuprofen formulation

The present invention is directed to methods of treating AERD (aspirin exacerbated respiratory disease) and/or asthma via the administration of a thromboxane receptor antagonist to a patient in need thereof.

Thromboxane receptor antagonists in AERD/asthma

The present invention is directed to methods of treating and/or ameliorating muscular dystrophy and/or treating cardiomyopathy in muscular dystrophy patients by administration of a therapeutically effective amount of a thromboxane Areceptor antagonist.

Compositions and methods of treating muscular dystrophy with thromboxane-Areceptor antagonists

[object Object]

Methods of treating at least one condition chosen from pain, inflammation, and fever in a critically ill patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen using a first dosage regimen, wherein the first dosage regimen produces a first pharmacokinetic profile in critically ill patients that is about equivalent to a second pharmacokinetic profile produced by administration of the intravenous pharmaceutical composition using a second dosage regimen of ibuprofen to non-critically ill patients, wherein the at least one condition of the critically ill patient is thereby treated.

Treating critically ill patients with intravenous ibuprofen

The present invention is directed to statin formulations having improved solubility and/or stability and methods for the same.

Stabilized statin formulations

Provided herein are liquid viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The liquid viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients and a liquid carrier. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.

Liquid viral formulations

Provided herein are lyophilized viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The lyophilized viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage.

Lyophilized viral formulations

Growing community of inventors

Cary, NC, United States of America

Leo Pavliv